Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Linda Schulte

Surgery Saint Louis, MO Medical Doctor

NPI 1477967644 CMS profile 405338

3023 N Ballas Rd Ste 150D, Saint Louis, MO 63131

Open in the dashboard

General payments

$12,046

144 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Linda Schulte of Saint Louis, MO is reported in the CMS Open Payments database as having received $12,046 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,047 61
2024 General $1,254 30
2023 General $1,056 13
2022 General $3,176 36
2021 General $108 1
2020 General $339 2
2019 General $66 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Linda Schulte
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Linda Schulte were reported at $6,047. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Linda Schulte Surgery median Middle half National median
2019 $66 $253 $82–$1,521 $163
2020 $339 $131 $40–$706 $114
2021 $108 $168 $50–$904 $132
2022 $3,176 $224 $76–$1,218 $149
2023 $1,056 $253 $82–$1,255 $160
2024 $1,254 $279 $90–$1,381 $164
2025 $6,047 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $7,698 80 payments
  2. Abiomed $1,065 17 payments
  3. Medtronic, Inc. $1,029 11 payments
  4. Medical Device Business Services, Inc. $413 2 payments
  5. CryoLife, Inc. $384 5 payments
  6. Atricure, Inc. $381 4 payments
  7. Bolton Medical Inc $282 4 payments
  8. W. L. Gore & Associates, Inc. $179 5 payments
  9. Zimmer Biomet Holdings, Inc. $158 4 payments
  10. DePuy Synthes Sales Inc. $112 3 payments
  11. Other $346 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,369 123 payments
  2. Travel and Lodging $3,614 17 payments
  3. Consulting Fee $2,650 2 payments
  4. Education $413 2 payments
Products named General payments · program years 2019–2025
  1. SAPIEN 3 Ultra RESILIA $2,120 1 payment
  2. EVOQUE $1,553 8 payments
  3. COREVALVE EVOLUT R $1,016 10 payments
  4. Impella $707 7 payments
  5. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $530 1 payment
  6. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $413 9 payments
  7. ATRICLIP LAA EXCLUSION SYSTEM $381 4 payments
  8. ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER $250 2 payments
  9. BIOGLUE SURGICAL ADHESIVE $250 2 payments
  10. CRYOVALVE SG PULMONARY HUMAN HEART VALVE $250 2 payments
  11. Other $1,967 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

267

Median for Thoracic Surgery: 42

Drug cost

$1,126

Median for Thoracic Surgery: $318

Branded share of claims

26.6%

Median for Thoracic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 71 $539
Metoprolol Tartrate Generic 52 $133
Potassium Chloride Generic 27 $130
Atorvastatin Calcium Generic 29 $103
Metoprolol Succinate Generic 19 $93
Rosuvastatin Calcium Generic 13 $41
Furosemide Generic 32 $41
Amlodipine Besylate Generic 12 $27
Carvedilol Generic 12 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 910 Part D prescribers listed as Thoracic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$126,633

Medicare's payments for the services billed

Medicare patients

101

Average age 75

Services billed

299

33 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Atrial fibrillation 66%
Heart failure 58%
Arthritis 57%
Chronic kidney disease 48%
Diabetes 37%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record